EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Fulminant Immune Checkpoint Inhibitor‐Related Encephalitis (ICI‐Encephalitis) Presenting Rapidly After First Infusion of Nivolumab: A Case Report

Jonathan Markle iD, Audrey Garza, Alyson Auriemma iD, Nicholas Rushlow, Mackenzie Eickhoff, Charles Bane iD

Case Reports in Oncological Medicine · 2026-01 · 2026 (1)

DOI: 10.1155/crom/6122845 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncological Medicine, online erschienen am 30.07.2026. Verfasst von Jonathan Markle und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Wright State University Boonshoft School of Medicine, Dayton, Ohio, USA, wright.edu. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors (ICIs) are increasingly used in oncologic clinical practice, leading to a corresponding rise in immune‐related adverse events (irAEs). In this context, we present a case of fulminant ICI‐associated encephalitis (ICI‐encephalitis) presenting within 24 h after a single administration of nivolumab (a PD‐1 inhibitor), in a patient with recurrent Hodgkin lymphoma. Case Presentation After receiving outpatient nivolumab combined with brentuximab (an antibody–drug conjugate), the patient presented with altered mental status, status epilepticus, and abnormal signal in the bilateral temporal lobes as shown on brain magnetic resonance imaging (MRI). Lumbar puncture found pleocytosis and slight elevation in protein; there was no evidence of abnormal autoantibodies or pathogenic infection. Following multidisciplinary consultation, the patient was ultimately diagnosed with ICI‐encephalitis and began on empiric treatment with intravenous methylprednisolone dosed 1 g/day for 5 days, followed by 5 days of intravenous immunoglobulin (IVIG). The patient experienced resolution of electrographic seizures and gradual improvement of mental status toward baseline but had persistent short‐term memory loss and did not experience complete brain MRI recovery. Ultimately, hospice placement was pursued after goals of care discussions with the patient′s spouse, and the patient expired within 1 month of discharge.

Conclusion

This case serves as a safety signal for rapidly presenting ICI‐encephalitis following nivolumab.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitor-related encephalitis (ICI-encephalitis)immune checkpoint inhibitors (ICIs)neurologic immunotherapy-related adverse event (NirAE)nivolumabprogrammed cell death-1 (PD-1)

Autor:innen und Institutionen

  • Department of Internal Medicine, Wright State University Boonshoft School of Medicine, Dayton, Ohio, USA, wright.edu.
  • Wright-Patterson Air Force Base, Department of Medicine, Dayton, Ohio, USA, af.mil.
  • Department of Graduate Studies, Wright State University Boonshoft School of Medicine, Dayton, Ohio, USA, wright.edu.
  • Dayton Physicians LLC, Miami Valley Hospital North, Dayton, Ohio, USA.

ORCID-Profile: Jonathan Markle, Alyson Auriemma, Charles Bane

Zitieren

APA

Markle, J., Garza, A., Auriemma, A., Rushlow, N., Eickhoff, M., & Bane, C. (2026). Fulminant Immune Checkpoint Inhibitor‐Related Encephalitis (ICI‐Encephalitis) Presenting Rapidly After First Infusion of Nivolumab: A Case Report. Case Reports in Oncological Medicine, 2026(1). https://doi.org/10.1155/crom/6122845

Vancouver

Markle J, Garza A, Auriemma A, Rushlow N, Eickhoff M, Bane C. Fulminant Immune Checkpoint Inhibitor‐Related Encephalitis (ICI‐Encephalitis) Presenting Rapidly After First Infusion of Nivolumab: A Case Report. Case Reports in Oncological Medicine. 2026;2026(1). doi:10.1155/crom/6122845

BibTeX
@article{Markle2026,
  author = {Markle, Jonathan and Garza, Audrey and Auriemma, Alyson and Rushlow, Nicholas and Eickhoff, Mackenzie and Bane, Charles},
  title = {Fulminant Immune Checkpoint Inhibitor‐Related Encephalitis (ICI‐Encephalitis) Presenting Rapidly After First Infusion of Nivolumab: A Case Report},
  journal = {Case Reports in Oncological Medicine},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crom/6122845}
}
Kostenlos starten →